Asia Pacific Advanced Wound Care Market size surpassed USD 1.7 billion in 2020 and is estimated to observe a growth rate of 6.1% from 2021 to 2027.
Increasing prevalence of chronic wounds including venous leg ulcers, acute wounds, and diabetic foot ulcers in developing countries of Asia Pacific will augment market growth. Rising cases of traumatic, surgical wounds will increase the number of patients undergoing wound care treatment. In addition, rising preference towards advanced wound care over traditional wound care owing to faster healing and efficiency in management of wounds will spur the APAC advanced wound care industry demand.
Get more details on this report - Request Free Sample PDF
Wound therapy devices segment revenue was around USD 600 million in 2020 on account of surging prevalence of ulcers coupled with technological advancements incorporated within wound therapy devices such as pressure relief devices (PRD). Pressure relief devices are utilized in curing the pressure sores, bed sores and decubitus ulcers. Similarly, these devices provide quick relief in the areas of localized damage to the skin.
Venous legs ulcers segment held more than 14.5% market share in 2020. Venous skin ulcer is a long-lasting sore on the legs that takes 4-6 weeks to heal and requires advanced wound care therapy that will positively influence the segment expansion. Usually, dressings and surgeries are the most preferred modes of treatment for venous leg ulcers that will increase the demand for advanced wound care therapies.
Get more details on this report - Request Free Sample PDF
The hospitals segment is predicted to register a CAGR of over 5% through 2027. Hospitals will hold regional dominance owing to rise in hospital stays of patients suffering from acute or chronic wounds. Presence of superior healthcare professionals and availability of advanced equipment in hospitals making it preferable option for treatment among patients.
The Japan advanced wound care market size accounted around USD 480 million in 2020. Increasing funding for wound care research in developing countries such as Japan will offer lucrative growth opportunities.
Due to recent outbreak of COVID-19, several hospital outpatient-based wound care departments of Japan have been placed in the non-essential group by many hospitals, hindering the market growth. This has become difficult situation for the patients with chronic wounds such as pressure ulcers, diabetic foot ulcers, venous ulcers, arterial ulcers, and others. Also, the wound care service providers are working to limit clinic visits and transfer as many patients as practical to tele-health treatment due to COVID-19 restrictions.
Some of the prominent players functioning in Asia Pacific market are 3M, Medtronic, B. Braun, Hollister, Integra LifeSciences Corporation, Smith & Nephew, Lohmann & Rauscher, and others.
These companies are adopting strategies such as expansion and innovations in product to expand their customer base and maintain financial stability. For instance, in May 2017, Mölnlycke announced launch of Mepilex Border Sacrum and Mepilex Border Heel Dressings, new wound care products for treatment and prevention of pressure ulcers.